Media ReleasesTelezon Limited

View All Telezon Limited News


Telezon Ltd Announces Serum Institute of India Boosts Its SoloFlow® Stock

HIGHLIGHTS: 
 
-  950,000 SoloFlow® Non-Injection Needles ordered by Serum Institute of India (“SII”) – the third order for SII.
 
The Board of Telezon® Limited (“the Company”) is pleased to announce that the Serum Institute of India (SII) has placed a third commercial order with Telezon for supply of SoloFlow® Non-Injection Needles. SII, the world’s largest producer of Measles and DTP vaccines, will use the new order of 950,000 SoloFlow® needles as a key component in their influenza vaccine kits. The vaccine kits are then distributed to the market for use in remote vaccination campaigns, areas that are almost inaccessible for even the simplest forms of healthcare.
 
 
For further information please download PDF attached:
Download this document